Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18482448 | ANTI-PTCRA ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 19329403 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | Non-Final OA | Avidity Biosciences, Inc. |
| 18629314 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | Non-Final OA | Novartis AG |
| 18178886 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Final Rejection | Novartis AG |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | Final Rejection | Genentech, Inc. |
| 17641736 | Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity | Non-Final OA | AMGEN INC. |
| 17507511 | ACTIVATABLE THERAPEUTIC MULTISPECIFIC POLYPEPTIDES WITH EXTENDED HALF-LIFE | Final Rejection | Hoffmann-La Roche Inc. |
| 17507029 | THERAPEUTIC MULTISPECIFIC POLYPEPTIDES ACTIVATED BY POLYPEPTIDE CHAIN EXCHANGE | Final Rejection | Hoffmann-La Roche Inc. |
| 18295822 | STABILIZED ACE2 VARIANT, ACE2-FC FUSION PROTEIN USING SAME, AND METHOD FOR PREVENTING OR TREATING COVID-19 | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 19098785 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | Non-Final OA | Minerva Biotechnologies Corporation |
| 19002112 | DIMERIC ANTIBODIES AND THEIR METHODS OF MANUFACTURE | Final Rejection | Medicovestor, Inc. |
| 17906792 | In vivo targeting of CD4+-T cells for mRNA therapeutics | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18653316 | INTRACELLULAR DELIVERY COMPOSITIONS | Final Rejection | Biond Biologics Ltd. |
| 17917523 | TARGETED REDUCTION OF ACTIVATED IMMUNE CELLS | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 17727395 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | Non-Final OA | SUTRO BIOPHARMA, INC. |
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | Non-Final OA | ZYMEWORKS BC INC. |
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | Non-Final OA | INNATE PHARMA |
| 18028420 | THERAPEUTIC USE, FOR NEURODEGENERATIVE DISEASES, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF | Non-Final OA | HANMI PHARM. CO., LTD. |
| 17907659 | MULTISPECIFIC ANTIBODY AND METHOD FOR PRODUCING SAME | Non-Final OA | University Public Corporation Osaka |
| 17939736 | PRODUCTION OF HETERODIMERIC PROTEINS | Final Rejection | Genmab A/S |
| 18463715 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | Non-Final OA | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 17312193 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | Non-Final OA | Sapreme Technologies B.V. |
| 18024486 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | Non-Final OA | Dyne Therapeutics, Inc. |
| 18116172 | METHODS FOR THE PREPARATION OF BIOCONJUGATES | Non-Final OA | Synaffix B.V. |
| 17301599 | ANTIBODIES AND CONJUGATES THEREOF | Final Rejection | KODIAK SCIENCES INC. |
| 18107265 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | Cue Biopharma, Inc. |
| 17923070 | Hypoimmunogenic Cells and Uses Thereof in Immune Responses | Non-Final OA | RXCELL INC. |
| 17012102 | DIMERIC PROTEIN WITH TRIPLE MUTATIONS | Final Rejection | GENMAB B.V. |
| 17774906 | FENTANYL HAPTEN, FENTANYL HAPTEN-CONJUGATES, AND METHODS FOR MAKING AND USING | Final Rejection | RTI INTERNATIONAL |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy